2024
Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.
Odzer N, Pusztai L, Rozenblit M. Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey. Journal Of Clinical Oncology 2024, 42: 1104-1104. DOI: 10.1200/jco.2024.42.16_suppl.1104.Peer-Reviewed Original ResearchMultimodal therapySurgical resectionOverall survivalPrimary tumorRandomized trialsResponse to initial chemotherapyTreated with multimodality therapyOligometastatic breast cancerRecommended surgical resectionLocally advanced cancerPalliative systemic chemotherapyProlonged overall survivalTime of diagnosisRandomized clinical trialsOS benefitSystemic chemotherapyInitial chemotherapyResidual lesionsSurvival benefitNCCN GuidelinesReceptor subtypesRetrospective studyTreatment modalitiesMetastatic cancerAblative radiation
2006
Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy
Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M. Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy. Cancer 2006, 109: 496-501. PMID: 17149760, DOI: 10.1002/cncr.22418.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCyclophosphamideEpirubicinFemaleFluorouracilHumansKineticsMiddle AgedNeoadjuvant TherapyPrognosisProspective StudiesReceptor, ErbB-2TrastuzumabConceptsPrimary breast cancerPathological complete responseBreast cancerECD levelsPrimary chemotherapyNeoadjuvant therapyPathological responseWeek 6HER-2 extracellular domainWeek 3HER-2/neu receptorCycles of fluorouracilCycles of paclitaxelNeu extracellular domainTrastuzumab-based regimensUtility of quantitationInitiation of chemotherapyExtracellular domainSame chemotherapyWeekly trastuzumabInitial chemotherapyNeoadjuvant chemotherapyComplete responseTreatment regimenResidual disease